Merck trims operations post-merger
This article was originally published in The Tan Sheet
Executive Summary
Merck plans to phase out operations at eight research and eight manufacturing sites as part of its goal to wring $3.5 billion in annual cost savings from its acquisition of Schering-Plough by 2012. In a July 8 release, Merck said the changes position the firm to "invest in key areas for future growth," including consumer care. The firm originally expected to cut about 15,000 jobs in the initial restructuring phase; it employed 100,000 as of December 2009. Merck expects the manufacturing and research cuts to save $2.7 billion to $3.1 billion by 2012. The $3.5 billion goal aligns with expectations provided in March 2009 when the firms announced the merger. The merger made Merck a competitor in the consumer products market with Schering OTC brands including MiraLAX laxative, Coppertone skin care, Afrin decongestant, Claritin allergy relief and Dr. Scholl's foot care products (1"The Tan Sheet" Feb. 22, 2010)
You may also be interested in...
Merck Appoints Consumer Head To Help Division Expand Globally
Merck appoints former Johnson & Johnson executive Bridgette Heller to steer its newly acquired consumer health division toward global expansion
Korean Bioclusters Offer Tax, Other Incentives To Attract Global Firms, Talent
South Korea has formulated new detailed policy measures to support the formation of major bioclusters, which will offer tax and other incentives in a bid to lure foreign firms and talent.
CDC Panel Backs Pfizer’s Maternal RSV Vaccine But Leaves Room For AstraZeneca/Sanofi’s Beyfortus
Abrysvo is recommended for use in pregnant people 32-36 weeks gestation if administered from September to January. For infants whose mothers were not vaccinated in this window, nirsevimab is recommended for prevention of respiratory syncytial virus infection.